NSE SME Ganga Bath Fittings opens hot, cools off quickly
The scrip was listed at Rs 59, a premium of 20.41% compared with the initial public offer (IPO) price. The stock was currently frozen at its lower limit of 5% over its listing price.
The counter hit a high of Rs 59 and a low of Rs 56.05. About 15.36 lakh shares of the company changed hands at the counter.
Ganga Bath Fittings' IPO was subscribed 1.61 times. The issue opened for bidding on 4 June 2025 and it closed on 6 June 2025. The price band of the IPO was set at Rs 46- 49 per share.
The IPO comprised of a fresh issue of 66,63,000 equity shares. The promoter and promoter group shareholding diluted to 69.16% from 98.81% pre-issue.
The company intends to utilize the net proceeds to meet capital expenditure towards purchase of equipments/machineries, repayment/prepayment of certain borrowings, working capital and general corporate purposes.
Ganga Bath Fittings is a manufacturing company specializing in a wide range of bathroom accessories and fittings. The company is engaged in the production and supply of high-quality products including, but not limited to, CP taps and components, showers, sanitary ware, ABS showers, ABS health faucets, ABS taps and accessories, PTMT taps, door handles, bathroom vanities, sinks, stainless steel (SS) showers, shower drains, and SS channel drainers. With a diverse product portfolio, the company caters to both residential and commercial bathroom fitting needs, ensuring functionality, durability, and modern design. It sells its products under its brand name such as Ganga, Glimpse, Stepian, and Tora. The company has 123 employees.
The company recorded revenue from operations of Rs 22.45 crore and net profit of Rs 3.60 crore for the period ended 31 December 2024.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Hans India
a few seconds ago
- Hans India
India's tourism sector projected to generate over $59 billion by 2028: Report
The Indian tourism sector is expected to generate over Rs 5,12,356 crore (over $59 billion) by 2028, with foreign tourist arrivals (FTAs) hitting 30.5 million, a report said on Saturday. Domestic tourism is on fire, expected to double to 5.2 billion visits by 2030 from 2.5 billion in 2024 (13.4 per cent CAGR), said the report by Capitalmind PMS, citing Ministry of Tourism data. According to the report, India's travel boom is picking up fast as more money in people's pockets and better transport are leading to record trips within the country and more foreign visitors for luxury and cultural stays. Domestic visitor spending grew from Rs 12.74 trillion in 2019 to Rs 14.64 trillion in 2023 and is projected to hit Rs 33.95 trillion by 2034 (7.9 per cent CAGR). Improved connectivity — air, road, and rail — plus tourism infrastructure investments are supercharging this growth. Domestic air passenger traffic is set to more than double to 693 million by FY30 from 307 million in FY24, the report stated. The travel market is set to soar from $75 billion in FY20 to $125 billion by FY27. Domestic tourism is the real MVP, with Domestic Tourist Visits (DTVs) jumping 44.98 per cent from 1,731.01 million in 2022 to 2,509.63 million in 2023. Uttar Pradesh (478.53 million) and Tamil Nadu (286.01 million) led the pack, while Maharashtra (3.39 million) and Gujarat (2.81 million) topped foreign tourist visits, the report highlighted. FTAs reached 18.89 million in 2023, surpassing the 2019 peak of 17.91 million by 5.47 per cent. As per the report, South Asia (29.02 per cent), North America (21.82 per cent), and Western Europe (20.40 per cent) were the top sources, with leisure travel (46.2 per cent), diaspora visits (26.9 per cent), and business travel (10.3 per cent) driving arrivals. Foreigners are now skipping Europe for India's luxury wellness retreats. Ayurveda resorts, palace stays, yoga spas: all booked out. India's value for luxury is slowly getting noticed, the report noted.
Fashion Value Chain
a few seconds ago
- Fashion Value Chain
Supriya Lifescience Q1 FY26 Revenue at Rs 145 Cr
Supriya Lifescience Ltd., a cGMP-compliant API manufacturer with a presence in over 86 countries, has announced its unaudited Q1 FY26 financial results. The company operates across multiple therapeutic categories, including anti-histamine, anti-allergic, vitamin, anaesthetic, and anti-asthmatic segments. Consolidated Financial Results (Q1 FY26 vs Q1 FY25): Revenue: Rs 145.07 crore, down 9.7% YoY (vs Rs 160.63 crore) EBITDA: Rs 51.7 crore (vs Rs 62.54 crore) EBITDA Margin: 35.6% (vs 38.9%) PAT: Rs 34.79 crore (vs Rs 44.64 crore) PAT Margin: 24.0% (vs 27.8%) Quarterly EPS: Rs 4.3 (vs Rs 5.5) Operational Highlights: Anaesthetic segment drove revenue, contributing 53% vs 45% in Q1 FY25. European markets' share rose to 41% from 34% last year. Capacity utilisation improved to 76% in FY26 from 70% in FY25. Acquired three land parcels near existing plants to support future growth. Management Comment: Mr. Satish Wagh, Chairman and Managing Director, stated, 'Our Q1 results reflect temporary impact from necessary repairs at the Lote facility to enhance efficiency and support new product launches. Despite revenue decline, margins stayed robust at 36% owing to backward integration and stronger regulated market contributions. With the Ambernath site nearing commercialisation in Q4, 3–4 new product launches in FY26, and sustained demand across key therapeutic areas, we anticipate recovery in H2 and remain confident of achieving ~20% growth and Rs 1,000 crore revenue by FY27.' Supriya Lifescience continues to strengthen its API portfolio with expansion plans, capacity enhancements, and a focus on regulated markets.
News18
10 minutes ago
- News18
Mumbai businessman loses Rs 5.24 cr in investment scam; four held
Agency: PTI Last Updated: Mumbai, Aug 16 (PTI) Four cyber fraudsters have been arrested for allegedly duping a businessman from Mumbai of Rs 5.24 crore by posing as executives of a Dubai-based investment company, police said on Saturday. The fraud came to light after the accused themselves invited the victim to Dubai, where he found that the company does not exist, an official said. A probe has revealed that the accused, who were recently apprehended from different parts of the country, had used the same modus operandi to cheat people of more than Rs 65 crore in Bengaluru, Chennai, Mumbai, Pune and Kerala, an official said. Three of the accused have been identified as R. Menon (35), Manikandan (32) and H. Pandi, he said. The official said that in October last year, a 65-year-old businessman from the western suburbs received a call from one of the accused, who posed as an employee of a Dubai-based investment company. The caller offered him attractive returns on investment in the company, he said. As the businessman showed interest in investing, the caller introduced him to the firm's director, who offered him 10 per cent returns per month and shares of the same value of the company, the official said. He said that the complainant then deposited money in November and noticed that the bank account used for the transaction was a personal account. On inquiry, the firm's director claimed that the account belonged to an employee and that the sum would be transferred to the company, the official said. In March, the accused invited the complainant for a visit to Dubai, where he found that the firm, in which he had invested Rs 5.24 crore over four months, did not exist. The official said when the businessman tried to contact the firm's owner, he was told that the latter was in the US, and when he demanded the return of his investment, the accused allegedly sent him fake cheques, demand drafts and other documents. PTI DC ARU view comments First Published: August 16, 2025, 13:15 IST Disclaimer: Comments reflect users' views, not News18's. Please keep discussions respectful and constructive. Abusive, defamatory, or illegal comments will be removed. News18 may disable any comment at its discretion. By posting, you agree to our Terms of Use and Privacy Policy.
